OSI-930 + erlotinib

OSI-930 + erlotinib is a combination of two small molecule tyrosine kinase inhibitors investigated for the treatment of advanced solid tumors. OSI-930 is an orally active, multi-targeted tyrosine kinase inhibitor that acts predominantly against VEGF receptors (VEGFR), c-Kit, and platelet-derived growth factor receptors. It inhibits tumor cell proliferation and angiogenesis by blocking these pathways[3][5][6]. Erlotinib is a well-established epidermal growth factor receptor (EGFR) inhibitor used in various cancers. The combination aims to co-inhibit multiple signaling pathways involved in tumor growth and resistance mechanisms. Clinical studies have evaluated the safety, pharmacokinetics, and recommended dosing of this combination in patients with advanced solid tumors[2][7]. Disease stabilization has been observed in some patients during trials.

Other names

SIM-930 (for OSI-930)